This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Previously, the Federal Court of Australia ruled that Australian patentlaw did not preclude “non-human” inventors from owning patents over their creations because no mental state of an inventor is required for an invention. What Does This Mean in the Canadian Context? In Apotex Inc v Wellcome Foundation.,
However, this 2002 decision did not define whether AI technology can be an inventor. Justice Marcus Smith explained his reasoning by saying that the meaning of the word “inventor” is limited to people under UK patentlaw. Canada: Apotex Inc v Wellcome Foundation Ltd [2002] 4 SCR 153.
Here is our recap of last week’s top IP developments including summaries of the posts on IPO’s patentapplication rejection of HIV drug Dolutegravir, another judgement in the long-running Section 3(k) saga, this time on the patentability of business methods and the DHC IPD’s Annual Report 2023-24. In this post by Kartikeya S.,
Highlights Moving Towards a Wrongful Obtainment Standard Part I Wrongful obtainment is a less explored area of patentlaw in the Indian context. Patent Office orders have partially answered what it means to wrongfully obtain a patent but are inconsistent in adjudicating wrongful obtainment claims. Vennootschap (Sr.
In 2002, the Federal Trade Commission, after an extensive inquiry, found out that over 75% of applications by generic pharmaceutical manufacturers were in some way or other involved in litigation initiated by the original patent holders. India changed its PatentsLaws in 2005 to comply with the TRIPS Agreement.
2022) focuses on the classic patentlaw question of whether the inventor’s pre-filing sales activity serve to bar the patent from issuing. Application of the on sale bar is a question of law as is the underlying issue of whether the experimental use exception applies. 2002) quoting Group One, Ltd.
Currently, Indian patentlaws are rather inchoate when it comes to granting patents for Ayurvedic medicines. Subsequently, CSIR requested the USPTO to re-examine the patentapplication. Upon re-examination, the examiner rejected the claims that were put forth by the applicants.
Article 84 of the European Patent Convention (EPC) requires that the claims of a European patentapplication “shall define the matter for which protection is sought” and “shall be clear and concise and be supported by the description.”[i] application; and (d) “relevant and not related to unique aspects of foreign patentlaw.”[xi].
‘The Paris Convention’, adopted in March 1883 and revised in the years 1900, 1911, 1925, 1934, 1958, 1967, and 1979, comprehensively addresses “patents, utility models, industrial designs, trademarks, service marks, trade names, and geographical indications”. [1] 8 (1994): 2621–29. [8] 9] “WIPO Copyright Treaty, Dec. 20, 1996, S. Treaty Doc.
The court has noted several factors that support the Applicants’ position. Since the tentative specification date in 2002, the Respondent has refrained from expressing any objections, even subsequent to the launch of the product (Bajaj Pulsar motorbike) onto the market. The idea of presuming the validity of a patent.
Initially, laws relating to patents in India did not cover inventions related to biotechnology until an amendment in 2002 acknowledged biotechnological, biochemical and microbiological processes as having the potential to be patented. whether or not these are part of the subject matter of a patentable innovation.
Even before the decision, biotech -focused patent attorneys have been searching for ways to capture their clients innovations with broad enough coverage. Xencor’s patentapplication (U.S. Application No. although in both a murine (mouse-derived) version and its humanized form, eculizumab. Dror , 112 F.3d
As a result, it is apparent that patentlaw offers a broader scope of protection in contrast to copyright law, which is primarily relied upon by inventors in this field. PROTECTION UNDER PATENTS ACT, 1970 The protection of CRIs has not been a straightforward journey. Controller of Patents & Rediff.com India Ltd.
PatentNext Summary: In some instances, software-based patentapplications can fail to include a sufficient algorithm describing “how” the software interacts with the underlying hardware of the invention. Therefore, as a general rule, software-related patents should include an algorithm. ” MPEP § 2164.
Eset, LLC, a patent case. As one might imagine, patentlaw frequently comes down to what particular terms in a patent mean, and because the whole point of a patent is to describe a new invention, existing language may sometimes now fully capture what an invention, or element thereof, really is. Vitronics Corp.
Having freelanced as a patent research analyst, he developed an interest in patent prosecution and in exploring the Patents Act through various interpretative approaches. He is currently engaged in WIPO-Harvard Law School Course in PatentLaw and Global Public Health. His previous post can be accessed here.
Long story short, somebody in the government should commission a patent landscape study to figure out just how many patentapplications have been filed for Cas9, as well as toolkits to deploy Cas9 in laboratories, before making any decisions to spend public money on a one nation, one licence option, as proposed in the Nature piece.
The Court also asserted the importance of both processes:- rigorous examinations for the focused evaluation against set legal standards so as to ensure only deserving applications receive patents; and the opposition process as a forum for external stakeholders to contribute to a more comprehensive evaluation of the patentapplication.
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content